OLEMA PHARMACEUTICALS, INC. Operating Income
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Operating Income of -$67.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$67.18M.
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$57.99M.
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$50.08M.
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$45.88M.
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for fiscal 2025 was -$178.70M.
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for fiscal 2024 was -$142.26M.
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for fiscal 2023 was -$104.96M.
- OLEMA PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was -$106.99M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$67.18M 10-Q · filed 2026-08-10 | -$125.17M 10-Q · filed 2026-08-10 | -$175.25M derived: sum of 3 quarters · filed 2026-08-10 | -$221.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$57.99M 10-Q · filed 2026-05-12 | -$108.07M derived: sum of 2 quarters · filed 2026-05-12 | -$153.95M derived: sum of 3 quarters · filed 2026-05-12 | -$201.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$50.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$95.96M derived: sum of 2 quarters · filed 2026-03-16 | -$143.82M derived: sum of 3 quarters · filed 2026-08-10 | -$178.70M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$45.88M 10-Q · filed 2025-11-10 | -$93.74M derived: sum of 2 quarters · filed 2026-08-10 | -$128.61M 10-Q · filed 2025-11-10 | -$165.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$47.86M 10-Q · filed 2026-08-10 | -$82.74M 10-Q · filed 2026-08-10 | -$119.50M derived: sum of 3 quarters · filed 2026-08-10 | -$157.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$34.87M 10-Q · filed 2026-05-12 | -$71.64M derived: sum of 2 quarters · filed 2026-05-12 | -$109.26M derived: sum of 3 quarters · filed 2026-05-12 | -$142.79M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$36.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$74.39M derived: sum of 2 quarters · filed 2026-03-16 | -$107.92M derived: sum of 3 quarters · filed 2026-03-16 | -$142.26M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$37.62M 10-Q · filed 2025-11-10 | -$71.15M derived: sum of 2 quarters · filed 2025-11-10 | -$105.49M 10-Q · filed 2025-11-10 | -$135.91M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$33.53M 10-Q · filed 2025-08-11 | -$67.87M 10-Q · filed 2025-08-11 | -$98.28M derived: sum of 3 quarters · filed 2025-08-11 | -$121.63M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$34.34M 10-Q · filed 2025-05-13 | -$64.75M derived: sum of 2 quarters · filed 2025-05-13 | -$88.10M derived: sum of 3 quarters · filed 2025-05-13 | -$109.70M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$30.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$53.76M derived: sum of 2 quarters · filed 2025-03-18 | -$75.36M derived: sum of 3 quarters · filed 2025-03-18 | -$104.96M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$23.34M 10-Q · filed 2024-11-12 | -$44.94M derived: sum of 2 quarters · filed 2024-11-12 | -$74.55M 10-Q · filed 2024-11-12 | -$101.76M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$21.60M 10-Q · filed 2024-08-06 | -$51.20M 10-Q · filed 2024-08-06 | -$78.42M derived: sum of 3 quarters · filed 2024-08-06 | -$101.64M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$29.60M 10-Q · filed 2024-05-08 | -$56.82M derived: sum of 2 quarters · filed 2024-05-08 | -$80.04M derived: sum of 3 quarters · filed 2024-05-08 | -$113.34M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$27.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$50.44M derived: sum of 2 quarters · filed 2024-03-11 | -$83.73M derived: sum of 3 quarters · filed 2024-03-11 | -$106.99M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$23.22M 10-Q · filed 2023-11-07 | -$56.52M derived: sum of 2 quarters · filed 2023-11-07 | -$79.77M 10-Q · filed 2023-11-07 | -$101.53M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$33.29M 10-Q · filed 2023-08-08 | -$56.55M 10-Q · filed 2023-08-08 | -$78.30M derived: sum of 3 quarters · filed 2023-08-08 | -$96.07M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$23.25M 10-Q · filed 2023-05-09 | -$45.01M derived: sum of 2 quarters · filed 2023-05-09 | -$62.77M derived: sum of 3 quarters · filed 2023-05-09 | -$79.30M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$21.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$39.52M derived: sum of 2 quarters · filed 2023-03-09 | -$56.04M derived: sum of 3 quarters · filed 2023-03-09 | -$71.49M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$17.76M 10-Q · filed 2022-11-08 | -$34.28M derived: sum of 2 quarters · filed 2022-11-08 | -$49.73M 10-Q · filed 2022-11-08 | -$59.87M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$16.52M 10-Q · filed 2022-08-09 | -$31.97M 10-Q · filed 2022-08-09 | -$42.10M derived: sum of 3 quarters · filed 2022-08-09 | -$49.97M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$15.45M 10-Q · filed 2022-05-09 | -$25.58M derived: sum of 2 quarters · filed 2022-05-09 | -$33.45M derived: sum of 3 quarters · filed 2022-05-09 | -$35.94M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$18.00M derived: sum of 2 quarters · filed 2022-02-28 | -$20.48M derived: sum of 3 quarters · filed 2022-02-28 | -$21.53M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$7.87M 10-Q · filed 2021-11-10 | -$10.35M derived: sum of 2 quarters · filed 2021-11-10 | -$11.40M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.49M 10-Q · filed 2021-08-10 | -$3.53M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$1.04M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$4.32M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |